Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Return on Sales (2023 - 2025)

Iovance Biotherapeutics has reported Return on Sales over the past 5 years, most recently at 0.83% for Q4 2025.

  • Quarterly results put Return on Sales at 0.83% for Q4 2025, up 24.0% from a year ago — trailing twelve months through Dec 2025 was 1.48% (up 78.0% YoY), and the annual figure for FY2025 was 1.48%, up 78.0%.
  • Return on Sales for Q4 2025 was 0.83% at Iovance Biotherapeutics, up from 1.35% in the prior quarter.
  • Over the last five years, Return on Sales for IOVA hit a ceiling of 0.83% in Q4 2025 and a floor of 447.6% in Q2 2023.
  • Median Return on Sales over the past 3 years was 2.36% (2025), compared with a mean of 100.14%.
  • Biggest five-year swings in Return on Sales: skyrocketed 44448bps in 2024 and later grew 7bps in 2025.
  • Iovance Biotherapeutics' Return on Sales stood at 241.41% in 2023, then skyrocketed by 100bps to 1.07% in 2024, then grew by 22bps to 0.83% in 2025.
  • The last three reported values for Return on Sales were 0.83% (Q4 2025), 1.35% (Q3 2025), and 1.86% (Q2 2025) per Business Quant data.